Search

Displaying results 2331 - 2340 of 2674 in total
  1. Drug

    Povidone

    go.drugbank.com/drugs/DB11061
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all intravenous drug products containing povidone.[L43942] Other formulations of povidone continue to be available.

  2. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).

    Categories: Programmed Death Receptor-1 Blocking Antibody
  3. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition

  4. Drug

    Givosiran

    go.drugbank.com/drugs/DB15066
    Approved

    [A187991] Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment

  5. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

  6. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    [A256047,A256052,A256057] The EMA approved the use of anacaulase in 2013,[A256047,A256052] and in January 2023, anacaulase received FDA approval.[L44717]

  7. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    [L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic

  8. Drug

    Recombinant stabilized RSV B prefusion F antigen

    go.drugbank.com/drugs/DB18714
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  9. Drug

    Milrinone

    go.drugbank.com/drugs/DB00235
    ApprovedInvestigational

    [A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]

  10. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1